JP Morgan Chase
ANTX icon

JP Morgan Chase’s AN2 Therapeutics ANTX Stock Holding History

JP Morgan Chase’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-49
Closed -$67 – 7045
2025
Q1 		$67 Sell
49
-3
-6% -$4 ﹤0.01% 6929
2024
Q4 		$72 Sell
52
-2
-4% -$2 ﹤0.01% 7060
2024
Q3 		$58 Sell
54
-966
-95% -$1.68K ﹤0.01% 7088
2024
Q2 		$2.19K Buy
+1,020
New +$2.43K ﹤0.01% 6514
2023
Q2 		– Sell
-8,511
Closed -$84K – 6896
2023
Q1 		$84K Buy
8,511
+2,247
+36% +$25K ﹤0.01% 5502
2022
Q4 		$60K Buy
6,264
+3,640
+139% +$48.7K ﹤0.01% 5553
2022
Q3 		$46K Buy
2,624
+145
+6% +$1.69K ﹤0.01% 5573
2022
Q2 		$19K Buy
+2,479
New +$32.8K ﹤0.01% 5902

Other funds holding ANTX

AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase's ANTX Position: Q2 2025 in Review

JP Morgan Chase sold out of AN2 Therapeutics (ANTX) in Q2 2025, closing a stake of 49 shares — an estimated $67 sold.

JP Morgan Chase first reported a position in ANTX in Q2 2022 and held it in 8 quarters. The position peaked at $84K in Q1 2023. 36 funds tracked by Wall St. Rank hold ANTX as of Q2 2025.

  • JP Morgan Chase reported no remaining AN2 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 49 AN2 Therapeutics shares in Q2 2025, an estimated $67.
  • JP Morgan Chase first reported a position in AN2 Therapeutics in Q2 2022 and held it in 8 quarters.
  • JP Morgan Chase's AN2 Therapeutics position peaked at $84K in Q1 2023.
  • 36 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.